Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

ClinicalTrials.gov ID: NCT02787551

Public ClinicalTrials.gov record NCT02787551. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 13, 2026, 10:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period

Study identification

NCT ID
NCT02787551
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sanofi
Industry
Enrollment
514 participants

Conditions and interventions

Interventions

  • Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor) Drug
  • Insulin glargine/lixisenatide fixed ratio combination Drug
  • albiglutide Drug
  • dulaglutide Drug
  • exenatide Drug
  • exenatide extended-release Drug
  • liraglutide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 5, 2016
Primary completion
May 24, 2018
Completion
Nov 16, 2018
Last update posted
Mar 24, 2022

2016 – 2018

United States locations

U.S. sites
74
U.S. states
26
U.S. cities
65
Facility City State ZIP Site status
Investigational Site Number 8400064 Birmingham Alabama 35205
Investigational Site Number 8400073 Fountain Hills Arizona 85268
Investigational Site Number 8400047 Phoenix Arizona 85028
Investigational Site Number 8400103 Bakersfield California 93309
Investigational Site Number 8400137 Fresno California 93720
Investigational Site Number 8400043 Huntington Park California 90255
Investigational Site Number 8400124 Lamont California 93241
Investigational Site Number 8400027 Lancaster California 93534
Investigational Site Number 8400098 Los Angeles California 90017
Investigational Site Number 8400013 Los Angeles California 90057
Investigational Site Number 8400042 Mission Hills California 91345
Investigational Site Number 8400006 Northridge California 91325
Investigational Site Number 8400021 Orange California 92868
Investigational Site Number 8400126 Rialto California 92377
Investigational Site Number 8400094 Santa Ana California 92704
Investigational Site Number 8400009 Ventura California 93003
Investigational Site Number 8400071 Denver Colorado 80209
Investigational Site Number 8400036 Denver Colorado 80246
Investigational Site Number 8400114 Jacksonville Florida 32216
Investigational Site Number 8400133 Miami Florida 33165
Investigational Site Number 8400058 Port Charlotte Florida 33952
Investigational Site Number 8400084 Tampa Florida 33612
Investigational Site Number 8400112 West Palm Beach Florida 33401
Investigational Site Number 8400045 Lawrenceville Georgia 30046
Investigational Site Number 8400096 Snellville Georgia 30078
Investigational Site Number 8400023 Springfield Illinois 62711
Investigational Site Number 8400049 Avon Indiana 46123
Investigational Site Number 8400053 Avon Indiana 46123
Investigational Site Number 8400085 Avon Indiana 46123
Investigational Site Number 8400120 Avon Indiana 46123
Investigational Site Number 8400041 Evansville Indiana 47714
Investigational Site Number 8400038 Indianapolis Indiana 46254-5469
Investigational Site Number 8400130 Council Bluffs Iowa 51501
Investigational Site Number 8400034 Lexington Kentucky 40503
Investigational Site Number 8400091 Lexington Kentucky 40503
Investigational Site Number 8400078 Marrero Louisiana 70072
Investigational Site Number 8400032 Metairie Louisiana 70006
Investigational Site Number 8400088 New Orleans Louisiana 70121
Investigational Site Number 8400033 Baltimore Maryland 21237
Investigational Site Number 8400051 Jefferson City Missouri 65109
Investigational Site Number 8400083 Papillion Nebraska 68046-3136
Investigational Site Number 8400044 Henderson Nevada 89052
Investigational Site Number 8400079 Albany New York 12206
Investigational Site Number 8400061 New York New York 10001
Investigational Site Number 8400123 North Massapequa New York 11758
Investigational Site Number 8400095 Staten Island New York 10301
Investigational Site Number 8400067 West Seneca New York 14224
Investigational Site Number 8400111 Yonkers New York 10704
Investigational Site Number 8400020 Morehead City North Carolina 28557
Investigational Site Number 8400065 Wilmington North Carolina 28401
Investigational Site Number 8400018 Fargo North Dakota 58104
Investigational Site Number 8400019 Columbus Ohio 43201
Investigational Site Number 8400056 Dayton Ohio 45439
Investigational Site Number 8400125 Mentor Ohio 44060
Investigational Site Number 8400099 Oklahoma City Oklahoma 73112
Investigational Site Number 8400129 Scottdale Pennsylvania 15683
Investigational Site Number 8400076 Smithfield Pennsylvania 15478
Investigational Site Number 8400104 Warwick Rhode Island 02886
Investigational Site Number 8400090 Columbia South Carolina 29204
Investigational Site Number 8400139 Austin Texas 78749
Investigational Site Number 8400001 Dallas Texas 75230-6885
Investigational Site Number 8400118 Edinburg Texas 78539
Investigational Site Number 8400008 Houston Texas 77004
Investigational Site Number 8400109 Houston Texas 77040
Investigational Site Number 8400063 Houston Texas 77061
Investigational Site Number 8400106 Houston Texas 77081
Investigational Site Number 8400014 North Richland Hills Texas 76180
Investigational Site Number 8400089 San Antonio Texas 78240
Investigational Site Number 8400135 Schertz Texas 78154
Investigational Site Number 8400075 Shavano Park Texas 78231
Investigational Site Number 8400107 Sugar Land Texas 77478
Investigational Site Number 8400054 Orem Utah 84058
Investigational Site Number 8400025 Salt Lake City Utah 84102
Investigational Site Number 8400092 Weber City Virginia 24290

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 50 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02787551, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 24, 2022 · Synced May 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02787551 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →